Where the capital flowed: the week in private credit & asset-based finance
Last week produced roughly $620.5 million of announced private credit and asset-based finance activity across seven transactions and the most revealing part isn’t the headline number. It’s the direction of travel.
Two of the week’s largest facilities refinanced borrowers out of bank debt and into non-bank ABL structures (one directly off J.P. Morgan), both marquee deals carried accordion features that price optionality straight into the capital stack, and a quiet tail of working-capital facilities quietly did the compounding that specialty finance is actually built on.
Eclipse Business Capital $300M ABL for ProFrac, refinanced off J.P. Morgan
Eclipse Business Capital provided a $300 million asset-based revolving credit facility to ProFrac Holding Corp (NASDAQ: ACDC), a technology-driven energy-services company.
The new line replaced ProFrac’s prior $275 million ABL facility that had been arranged by JPMorgan Chase, upsized the commitment, extended the maturity to July 2030, and added a $25 million accordion, with Eclipse acting as agent, collateral agent, lead arranger and book runner.
Why it matters:
This is the private-credit thesis compressed into one transaction: an independent, non-bank ABL platform winning a large, public-company mandate away from a money-center bank. It’s not distress, it’s a borrower choosing more flexible, collateral-driven capital and a longer runway. For allocators, it’s a live data point on how far into the large-corporate arena specialty ABL has moved.
Key risks:
Oilfield services is one of the more cyclical corners of the market. Revenue, receivables quality and equipment values all track a volatile commodity cycle, and a borrowing base built on receivables, inventory and specialized frac equipment can contract quickly in a downturn. Fleet utilization, customer concentration and collateral valuation cadence are the numbers that decide outcomes here.
Opportunities:
An asset-based structure gives strong collateral coverage and downside protection for the spread on offer, and the refinancing dynamic, banks stepping back from cyclical energy exposure, is exactly the gap specialty lenders are positioned to fill. Disciplined, high-frequency borrowing-base monitoring turns that cyclicality from a threat into a manageable, well-priced risk.
Voyager Technologies $250M J.P. Morgan-led facility, accordion to $400M
Voyager Technologies (NYSE: VOYG), a Denver-based defense and space company, closed an upsized $250 million credit facility led by J.P. Morgan. A Fourth Amendment to its existing agreement lifted commitments by $50 million (from $200 million to $250 million) and preserved an uncommitted accordion of up to a further $150 million, a potential total facility of $400 million. Proceeds support liquidity across the company’s space, defense and national-security portfolio.
Why it matters:
This is the counterpoint to the Eclipse story: where a bank fits the growth narrative, it competes hard. Defense and space have become a scale credit category that money-center balance sheets want exposure to, and the structure shows how optionality is now embedded directly into deals, the accordion lets the borrower add capacity without renegotiating from scratch.
Key risks:
The credit is tied to government budgets, program execution and long revenue-conversion cycles, with meaningful counterparty concentration in government end-customers. Voyager is also a growth-stage borrower carrying widening losses and finite cash runway, which makes covenant design at least as important as headline spread.
Opportunities:
Durable secular tailwinds, a marquee lead bank that de-risks diligence, and a liquid, syndicated structure make this an accessible way for managers to gain exposure to the defense-tech theme through participations. The lending edge is understanding contract backlog and milestone-based revenue rather than hard-asset collateral.
Wingspire Capital $45M revolver for a global spinal-surgery device maker
Wingspire Capital provided a $45 million revolving credit facility to a sponsor-backed, global medical-device maker specializing in spinal-surgery products, refinancing the company’s previous capital structure and adding liquidity for growth. Wingspire is a portfolio company of Blue Owl Capital, a reminder of how much institutional weight now sits behind “specialty” lending.
Why it matters:
Medical devices are one of the most defensive, least cyclical corners of the credit market, and this is a clean, growth-oriented refinancing rather than a rescue. The deal also underlines a structural theme: the capital behind mid-market ABL is increasingly the same institutional capital that funds large private credit, the distinction between “specialty” and “mainstream” is largely one of ticket size.
Key risks:
Regulatory and reimbursement dynamics, single-product-line concentration, and inventory and R&D build ahead of revenue all shape the collateral. Demand is durable, but FDA and payer decisions can move the risk profile faster than the top line.
Opportunities:
Resilient, recurring-revenue-style end demand makes this a lower-beta, stabilizing asset within a diversified private-credit book. A revolver structure keeps the lender close to the collateral while giving the borrower room to grow.
The quiet engine: four working-capital facilities that do the compounding
Individually small, collectively instructive, these four deals map the entire working-capital lifecycle, from funding an order before it’s built to advancing against the invoice after it ships.
Entrepreneur Growth Capital $15M ABL line (consumer products). EGC closed a $15 million asset-based line for a 50-year-old, family-owned Wisconsin consumer-products company navigating management turnover and “lender fatigue,” with availability against receivables, inventory, equipment and owned real estate.
- Why it matters: ABL is the natural home for turnaround and transition situations that banks exit.
- Key risks: execution risk on the turnaround, retail-channel concentration, inventory obsolescence.
- Opportunities: multi-collateral coverage and a high-touch structure that can reprice as the business stabilizes.
TradeCap Partners $5M purchase-order funding (sporting goods). Introduced by the company’s existing senior lender, TradeCap funded 100% of the direct cost of goods so a U.S. recreational sporting-goods manufacturer could fulfill large orders for national big-box retailers, underwritten in about ten business days.
- Why it matters: PO funding finances growth that a traditional line can’t, without diluting the owner.
- Key risks: performance and completion risk, seasonality, supplier and delivery dependence, single-order concentration.
- Opportunities: short-duration, self-liquidating exposure with strong structural control and high velocity.
Amerisource Business Capital $4.5M working-capital facility (industrial services). Amerisource refinanced a family-owned Michigan pipe-fabrication and millwrighting firm’s bank debt and added working capital, secured by receivables, inventory and commercial real estate.
- Why it matters: another borrower re-banking from a traditional lender into a more flexible ABL structure.
- Key risks: industrial end-market cyclicality and project-timing swings.
- Opportunities: collateral-rich, granular exposure with real-asset support.
Culain Capital $1M accounts-receivable financing (staffing). Culain converted eligible receivables into immediate liquidity for a California staffing company, funding payroll obligations that fall due long before customer invoices are paid.
- Why it matters: staffing lives or dies on payroll timing; A/R financing is the precise tool for that gap.
- Key risks: dilution, obligor concentration, verification risk, and sensitivity to the labor cycle.
- Opportunities: high-advance, fast-turning collateral with frequent repricing and tight monitoring.
Takeaways
- Borrowers are re-banking into non-banks. Multiple facilities last week refinanced away from bank debt, including a $300M public-company ABL taken directly off JPMorgan. Specialty lenders are winning on flexibility and speed, not just filling gaps banks leave behind.
- Where the growth story fits, banks still compete hard. J.P. Morgan leading Voyager’s upsized defense facility shows the market is bifurcating, not simply shifting one way.
- Optionality is being priced into the structure. Accordion features on both marquee deals (Voyager to $400M, Eclipse to $325M) give borrowers capacity without commitment and give lenders a longer relationship.
- “Specialty” is institutional. Blue Owl behind Wingspire, a large credit platform behind Eclipse, a hedge fund behind Culain, a bank behind TradeCap. The tail is not small money.
- One week spanned the full working-capital lifecycle, purchase-order funding, inventory and working-capital lines, and accounts-receivable financing, alongside large corporate revolvers. That collateral heterogeneity is the defining operational challenge of a modern private-credit book.
How Cardo AI helps Asset managers and Lenders
The through-line across every deal above from a $300 million public-company ABL to a $1 million staffing payroll line is that the operational job is identical: collect, normalize, monitor and report on loan- and collateral-level data, continuously and at scale. As portfolios diversify across sector, structure, collateral type and ticket size, that job is where the edge (and the risk) actually lives.
That’s the operating system Cardo AI provides for private credit and asset-based finance:
- Loan-tape ingestion across any source or format, one source of truth from fragmented originator and servicer data.
- Borrowing base, eligibility and waterfall computation automated, auditable, and refreshed as the collateral moves.
- Concentration, covenant and trigger monitoring, with early-warning signals before a breach becomes a loss.
- Portfolio analytics and stress testing, scenario analysis across cyclical and defensive exposures alike.
- Institutional-grade investor reporting, the transparency LPs and financing partners now expect.
- Multi-asset-class onboarding, from oilfield ABL and defense revolvers to purchase-order funding and staffing receivables, in one platform.
In a market this heterogeneous, the managers who win aren’t just chasing the highest headline yield, they’re the ones who can see a diversifying book at the loan and collateral level, in real time, and act before the risk moves.
Sources
ABL Advisor deal tables (July 6-10, 2026); company press releases via Business Wire, GlobeNewswire, PR Newswire and Bloomberg; ABF Journal; and issuer investor relations pages.
If you’re scaling an asset-based or private credit book, we should talk.